Pfizer Inc said Wednesday that booster doses of its COVID-19 vaccine can be given along with its pneumonia vaccine and produced strong immune and safety responses in people 65 and older in a late-stage study.
The study, started in May, tested the company’s next-generation pneumococcal conjugate vaccine, PREVNAR 20, with a third dose of the Pfizer-BioNTech COVID-19 injection in 570 participants.
The aim of the study was to test the safety of the combination and the immune response after adding the pneumonia vaccine to the existing COVID-19 vaccine.
The company said the responses elicited by PREVNAR 20 and a booster dose of the COVID-19 vaccine were similar when given together or with a placebo.
The data provides evidence supporting the potential of administering PREVNAR 20 and the company’s COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies to receive the recommended immunization, Pfizer said.
PREVNAR 20 was approved by the US Food and Drug Administration in June of last year to help protect adults against most invasive pneumococcal diseases and pneumonia.
Study participants were recruited from the companies’ late stage COVID-19 vaccine study and those who had received the second dose of the company’s COVID-19 vaccine at least six months prior to entering the co-administration study.
The latest tech news delivered to your inbox
The Inquirer Foundation supports our healthcare leaders and still accepts cash donations to deposit into the Banco de Oro (BDO) checking account # 007960018860 or donate through PayMaya using this Link .
Subscribe to MORE QUESTION to get access to The Philippine Daily Inquirer and more than 70 other titles, share up to 5 devices, listen to the news, download from 4am and share articles on social media. Call 896 6000.